Antiproteinase 3- and antimyeloperoxidase-associated vasculitis

Kidney International

Volumn 57, Issue 6, 2000, Pages 2195-2206

  Franssen, Casper F M ^a   Stegeman, Coen A ^a   Kallenberg, Cees G M ^a   Gans, Reinold O B ^a   De Jong, Paul E ^a   Hoorntje, Steven J ^a   Cohen Tervaert, Jan Willem ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ANCA; Myloperoxidase; Necrotizing crescentic glomerulonephritis; Proteinase 3; Systemic vasculitis; Wegener's granulomatosis

Indexed keywords

MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

DISEASE CLASSIFICATION; GLOMERULONEPHRITIS; HISTOPATHOLOGY; HUMAN; LUNG GRANULOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0034091281     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00080.x     Document Type: Article

References (145)

1. 1. DAVIES DJ, MORAN JE, NIALL JF, RYAN GB: Segmental necrotizing glomerulonephritis with antineutrophil antibody: Possible arbovirus etiology? Br Med J 285:606, 1982
2. 2. VAN DER WOUDE FJ, RASMUSSEN N, LOBATTO S, WIIK A, PERMIN H, VAN ES LA, VAN DER GIESSEN M, VAN DER HEM GK, THE TH: Autoantibodies to neutrophils and monocytes: A new tool for diagnosis and a marker of disease activity in Wegener's granulomatosis. Lancet 2:425-429, 1985
3. 3. FALK RJ, JENNETTE JC: Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318:1651-1657, 1988
4. 4. GOLDSCHMEDING R, VAN DER SCHOOT CE, COHEN TERVAERT JW, MASON DY, VON DEM BORNE AE, KALLENBERG CGM: Autoantibodies against myeloid lysosomal enzymes: A novel class of autoantibodies associated with vasculitic syndromes. Kidney Int 34: 558-559, 1988
5. 5. GOLDSCHMEDING R, VAN DER SCHOOT CE, TEN BOKKEL HUININK D, HACK CE, VAN DEN ENDE ME, KALLENBERG CGM, VON DEM BORNE AE: Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 84:1577-1587, 1989
6. 6. JENNETTE JC, HOIDAI JH, FALK RJ: Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. Blood 78:2263-2264, 1990
7. 7. SAXON A, SHANAHAN F, LANDERS C, GANZ T, TARGAN S: A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 86:202-210, 1990
8. 8. DUERR RH, TARGAN SR, LANDERS CJ, LARUSSO NF, LINDSAY KL, WIESNER RH, SHANAHAN F: Neutrophil cytoplasmic antibodies: A link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 100:1385-1391, 1991
9. 9. CAMBRIDGE G, RAMPTON DS, STEVENS TRJ, MCCARTHY DA, KAMM M, LEAKER B: Anti-neutrophil cytoplasmic antibodies in inflammatory bowel diseases: Prevalence and diagnostic role. Gut 33: 668-674, 1992
10. 10. MULDER AHL, HORST G, HAAGSMA EB, LIMBURG PC, KLEIBEUKER JH, KALLENBERG CGM: Prevalence and characterization of antineutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 17:411-417, 1993
11. 11. MULDER AHL, HORST G, VAN LEEUWEN MA, LIMBURG PC, KALLENBERG CGM: Antineutrophil cytoplasm antibodies in rheumatoid arthritis: Characterization and clinical correlations. Arthritis Rheum 36:1054-1060, 1993
12. 12. KLAASSEN RJL, GOLDSCHMEDING R, DOLMAN KM, VLEKKE ABJ, WEIGEI HM, EEFTINCK SCHATTENKERK JKM, MULDER JW, WESTEDI ML, VON DEM BORNE AE: Anti-neutrophil cytoplasmic antibodies in patients with symptomatic HIV infection. Clin Exp Immunol 87:24-30, 1992
13. 13. EFTHINIOU J, SPICKETT G, LANE D, THOMPSON A: Antineutrophil cytoplasmic antibodies, cystic fibrosis and infection. Lancet 337: 1037-1038, 1991
14. 14. MEZZANO S, VALDERRAMA G, OLAVARRIA F, ARDILES F, ARRIAGADA A, CASTILLO A, CAORSI I: Antineutrophil-cytoplasmic-autoantibodies in poststreptococcal nephritis, in ANCA-Associated Vasculitides: Immunological and Clinical Aspects, edited by GROSS WL, New York, Plenum Press, 1993, pp 449-453
15. 15. SUBRA JF, MICHELET C, LAPORTE J, CARRERE F, REBOUL P, CARTIER F, SAINT-ANDRÉ JP, CHEVAILLER A: The presence of cytoplasmic antineutrophil cytoplasmic antibodies (C-ANCA) in the course of subacute bacterial endocarditis with glomerular involvement, coincidence or association? Clin Nephrol 49:15-18, 1998
16. 16. PETER HH, METZGER D, RUMP A, RöTHER E: ANCA in diseases other than systemic vasculitis. Clin Exp Immunol 93(Suppl 1 ):12-14, 1993
17. 17. KALLENBERG CGM, MULDER AHL, COHEN TERVAERT JW: Antineutrophil cytoplasmic antibodies: A still-growing class of autoantibodies in inflammatory disorders. Am J Med 93:675-682, 1992
18. 18. GROSS WL, SCHMITT WH, CSERNOK E: ANCA and associated diseases: Immunodiagnostic and pathogenetic aspects. Clin Exp Immunol 91:1-12, 1993
19. 19. PEEN E, ALMER S, BODEMAR G, RYDER BO, SJOLIN C, TEJLE K, SKOGH T: Antilactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis and Crohn's disease. Gut 34:56-62, 1993
20. 20. HALBWACHS-MECARELLI LH, NUSBAUM EH, NOËL LH, REUMAUX D, ERLLNGER S, GRUNFELD JP, LESAVRE P: Antineutrophil cytoplasmic antibodies (ANCA) directed against vathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin Exp Immunol 90:79-84, 1992
21. 21. KANEKO K, SUZUKI Y, YAMASHIRO Y, YABUTA S: Is p-ANCA in ulcerative colitis directed against β-glucuronidase? Lancet 341:320, 1993
22. 22. SCHMIIT WH, CSERNOK E, FLESH BK, HAUSCHILD S, GROSS WL: Autoantibodies directed against lysosyme: A new target antigen for anti-neutrophil cytoplasmic autoantibodies. Adv Exp Med Biol 336:267-272, 1993
23. 23. JENNETTE JC, FALK RJ, ANDRASSY K, BACON PA, CHURG J, GROSS WE, HAGEN EC, HOLLMAN GS, HUNDER GG, KALLENBERG CGM, MCCLUSKEY RT, SINICO RA, REES AJ, VAN ES LA, WALDHERR R, WIIK A: Nomenclature of systemic vasculitides: Proposal of an international consensus conference. Arthritis Rheum 37:187-192, 1994
24. 24. NILES JL, MCCLUSKEY RT, AHMAD MF, ARNAOUT M: Wegener's granulomatosis autoantigen is a novel serine proteinase. Blood 74:1888-1893, 1989
25. 25. LÜDEMANN J, UTECHT B, GROSS WL: Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme. J Exp Med 171:357-362, 1990
26. 26. CAMPANELLI D, DETMERS PA, NATHAN CF, GABAY JE: Azurocidin and a homologeous serine protease from neutrophils: Differential antimicrobial and proteolytic properties. J Clin Invest 85:904-915, 1990
27. 27. KAM CM, KERRIGAN JE, DOLMAN KM, GOLDSCHMEDING R, VON DEM BORNE AE, POWERS JC: Substrate and inhibitor studies on proteinase 3. FEBS Lett 297:119-123, 1992
28. 28. GABAY JE, SCOTT RW, CAMPANELLI D, GRIFFITH J, WILDE C, MARRA MN, SEEGER M, NATHAN CF: Antibiotic proteins of human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 86:5610-5614, 1989
29. 29. WIESLANDER J, WIIK A: ANCA antigens: Proteinase 3, in Manual of Biological Markers of Disease, edited by VAN VENROOY WJ, MAINE RN, Dordrecht, Kluwer Academic, 1994, pp B7.1:1-9
30. 30. KAO RC, WEHNER NG, SKUBITZ KM, GRAY BH, HOIDAL JR: Proteinase 3: A distinct human polmorphonuclear leukocyte proteinase that induces emphysema in hamsters. J Clin Invest 82: 1963-1973, 1988
31. 31. HENSHAW TJ, MALONE CC, GABAY JE, WILLIAMS RC JR: Elevations of neutrophil proteinase 3 in serum of patients with Wegener's granulomatosis and polyarteritis nodosa. Arthritis Rheum 37:104-112, 1994
32. 32. WIESLANDER J, WIIK A: ANCA antigens: Myeloperoxidase, in Manual of Biological Markers of Disease, edited by VAN VENROOY WJ, MAINE RN, Dordrecht, Kluwer Academic, 1994, pp B7.2:1-9
33. 33. PRYZWANSKY MB, MARTIN LE, SPITZNAGEL JK: Immunocytochemical localization of myeloperoxidase, lactoferrin, lysosyme and neutral proteases in human monocytes and neutrophil granulocytes. J Reticuloendothel Soc 24:295-310, 1978
34. 34. HARRISON JE, SCHULTZ J: Studies on the chlorinating activity of myeloperoxidase. J Biol Chem 251:1371-1374, 1976
35. 35. WEISS SJ: Tissue destruction by neutrophils. N Engl J Med 320:365-376, 1989
36. 36. SAEKI S, KURODA T, MORITA T, SUZUKI K, ARAKAWA M, KAWASAKI K: Significance of myeloperoxidase in rapidly progressive glomerulonephritis. Am J Kidney Dis 26:13-21, 1995
37. 37. SFGELMARK M, PERSSON B, HELLMARK T, WIESLANDER J: Binding and inhibition of myelo-peroxidase (MPO): A major function of ceruloplasmin? Clin Exp Immunol 108:167-174, 1997
38. 38. GRIFFIN SV, CHAPMAN PT, LIANOS EA, LOCKWOOD CM: The inhibition of myeloperoxidase by ceruloplasmin can be reversed by antimyeloperoxidase antibodies. Kidney Int 55:917-925, 1999
39. 39. SOMMARIN Y, RASMUSSEN N, WIESLANDER J: Characterization of monoclonal antibodies to proteinase-3 and application in the study of epitopes for classical antineutrophil cytoplasm antibodies. Exp Nephrol 3:249-256, 1995
40. 40. WILLIAMS RC JR, STAUD R, MALONE CC, PAYABYAB J, BYRES L, UNDERWOOD D: Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. J Immunol 152:4722-4737, 1994
41. 41. BINI P, GABAY JE, TEHFL A, MELCHIOR M, ZHOU JL, ELKON KB: Antineutrophil cytoplasmic autoantibodies in Wegener's granulomatosis recognize conformational epitope(s) on proteinase 3. J Immunol 149:1409-1415, 1992
42. 42. CHANG L, BINOS S, SAVIGE J: Epitope mapping of antiproteinase 3 and antimyeloperoxidase antibodies. Clin Exp Immunol 102:112-119, 1995
43. 43. AUDRAIN MAP, BARANGER TAR, MOGUILEVSKI N, MARTIN SJ, DEVYS A, LOCKWOOD CM, MULLER JY, ESNAULI VLM: Antinative and recombinant monoclonals and human autoantibodies. Clin Exp Immunol 107:127-134, 1997
44. 44. SHORT AK, LOCKWOOD CM: Studies on epitope restriction on myeloperoxidase (MPO), an important antigen in systemic vasculitis. Clin Exp Immunol 110:270-276, 1997
45. 45. TOMIZAWA K, MINE E, FUJII A, OHASHI YY, YAMAGOF S, HASHIMOTO Y, ISHIDA-OKAWAR A, ITO M, TANOKURA M, YAMAMOTO T, ARIMURA Y, NAGASAWA T, MIZUNO S, SUZUKI K: A panel set for epitope analysis of myeloperoxidase (MPO)-specific antineutrophil cytoplasmic antibody MPO-ANCA using recombinant hexamer histidine-tagged MPO deletion mutants. J Clin Immunol 18:142-152, 1998
46. 46. FALK RJ, BECKER M, TERELI R, JENNETTE JC: Anti-myeloperoxidase autoantibodies react with native but not denatured myeloperoxidase. Clin Exp Immunol 89:274-278, 1992
47. 47. ROBERTS DE, PEEBLES C, CURD JG, TAN EM, RUBIN RL: Autoantibodies to native myeloperoxidase in patients with pulmonary hemorrhage and acute renal failure. J Clin Immunol 11:389-397, 1991
48. 48. PEDROLIO E, BLEH L, BAUTZ FA, KALDEN JA, BAUTZ EKF: Antineutrophil cytoplasmic autoantibodies (ANCA) recognizing a recombinant myeloperoxidase subunit. Adv Exp Med Biol 336:87-92, 1993
49. 49. WIEL A, DOLMAN KM, VAN DER MEER-GERRITSEN CH, HACK CE, VON DEM BORNE AE, GOLDSCHMEDING R: Interference of Wegener's granulomatosis autoantibodies with neutrophil proteinase 3 activity. Clin Exp Immunol 90:409-414, 1992
50. 50. DOLMAN KM, STEGEMAN CA, VAN DER WIEL BA, HACK CA, VON DEM BORNE AE, KALLENBERG CGM, GOLDSCHMEDING R: Relevance of classic antineutrophil cytoplasmic autoantibodies (c-ANCA) mediated inhibition of proteinase 3-α1-antitrypsin complexation to disease activity in Wegener's granulomatosis. Clin Exp Immunol 93:405-410, 1993
51. 51. DAOUK GH, PALSSON R, ARNAOUT MA: Inhibition of proteinase 3 by ANCA and its correlation with disease activity in Wegener's granulomatosis. Kidney Int 47:1528-1536, 1995
52. 52. BROUWER E, COHEN TERVAERT JW, HORST G, HUITEMA MG, VAN DER GIESSEN M, LIMBURG PC, KALLENBERG CGM: Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies in patients with Wegener's granulomatosis and clinically related conditions. Clin Exp Immunol 83:379-386, 1991
53. 53. KALLENBERG CGM, BROUWER E, WEENING JJ, COHEN TERVAERT JW: Anti-neutrophil cytoplasmic antibodies: Current diagnostic and pathophysiological potential. (Editorial Review) Kidney Int 46:1-15, 1994
54. 54. SAVAGE COS, HARPER L, ADU D: Primary systemic vasculitis. Lancet 349:553-558, 1997
55. 55. WANG G, CSERNOK E, DE GROOT K, GROSS WL: Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmic antibodies (ANCA). J Immunol Methods 208:203-211, 1997
56. 56. LIM LCL, TAYLOR JG, SCHMITZ JL, FOLDS JD, WILKMAN AS, FALK RJ, JENNETTE JC: Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serology. Am J Clin Pathol 111:363-369, 1999
57. 57. HAGEN EC, ANDRASSY K, CSERNOK E, DAHA MR, GASKIN G, GROSS W, HANSEN B, HEIGL Z, JAYNE D, KALLENBERG CGM, LESAVRE P, LOCKWOOD CM, LUDEMANN J, MASCART-LEMONE F, MIRAPEIX E, PUSEY C, RASMUSSEN N, SINICO RA, TZIOUFAS A, WIESLANDER J, WIIK A, VAN DER WOUDE FJ, EC/BCR PROJECT FOR ANCA ASSAY STANDARDIZATION: Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA): A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods 196:1-15, 1996
58. 58. HAGEN EC, DAHA MR, HERMANS J, ANDRASSY K, CSERNOK E, GASKIN G, LESAVRE, P, LUDEMANN J, RASMUSSEN N, SINICO RA, WIIK A, VAN DER WOUDE FJ, THE EC/BCR PROJECT FOR ANCA ASSAY STANDARDIZATION: Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA): A report on the second phase of an international cooperative study on the standardization of ANCA assays. Kidney Int 53:743-753, 1998
59. 59. COHEN TERVAERT JW, VAN DER WOUDE FJ, FAUCI AS, AMBRUS JL, VELOSA J, KEANE WF, MEYER S, VAN DER GIESSEN M, THE TH, VAN DER HEM GK, KALLENBERG CGM: Association between active Wegener's granulomatosis and cytoplasmic antibodies. Arch Intern Med 149:2461-2465, 1989
60. 60. NÖLLE B, SPECKS U, LÜDEMANN J, ROHRBACH MS, DEREMEE RA, GROSS WL: Anticytoplasmic autoantibodies: Their immunodiagnostic value in Wegener's granulomatosis. Ann Intern Med 111: 28-40, 1989
61. 61. WEBER MFA, ANDRASSY K, PULLIG O, KODERISCH J, NETZER K: Antineutrophil cytoplasmic antibodies and antiglomerular basement membrane antibodies in Goodpasture's syndrome and in Wegener's granulomatosis. J Am Soc Nephrol 2:1227-1234, 1992
62. 62. RAO JK, ALLEN NB, FEUSSNER JR, WEINBERGER M: A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis. Lancet 346:926-931, 1995
63. 63. COHEN TERVAERT JW, GOLDSCHMEDING R, ELEMA JD, VAN DER GIESSEN M, HUITEMA MG, KOOLEN MI, HENÉ RJ, VAN DER HEM GK, VON DEM BORNE AE, KALLENBERG CGM: Associations of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum 33:1264-1272, 1990
64. 64. GASKIN G, SAVAGE COS, RYAN JJ, JONES S, REES AJ, LOCKWOOD CM, PUSEY CD: Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 6:689-694, 1991
65. 65. GEFFRIAUD-RICOUARD C, NOËL LH, CHAUVEAU D, HOUHOU S, GRÜNFEED JP, LESAVRE P: Clinical spectrum associated with ANCA of defined specificities in 98 selected patients. Clin Nephrol 39:125-136, 1993
66. 66. COHEN TERVAERT JW, GOLDSCHMEDING R, ELEMA JD, VAN DER GIESSEN M, HUITEMA MG, VAN DER HEM GK, THE TH, VON DEM BORNE AE, KALLENBERG CGM: Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 37:799-806, 1990
67. 67. PUFIFIN DJ, DUURSMA J, GATHIRAM V, JACKSON TFGH: Invasive amoebiasis is associated with the development of antineutrophil cytoplasmic antibody. Clin Exp Immunol 97:48-51, 1994
68. 68. KALLENBERG CGM, COHEN TERVAERT JW: Antineutrophil cytoplasmic antibodies: New tools in the diagnosis and follow-up of necrotizing glomerulonephritis, in International Yearbook of Nephrology, edited by ANDREUCCI VA, FINE LG, London, Springer-Verlag, 1992, pp 313-335
69. 69. FRANSSEN CFM, GANS ROB, KALLENBERG CGM, HAGELUKEN C, HOORNTJE SJ: Disease spectrum of patients with anti-neutrophil cytoplasmic autoantibodies: Distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med 244:209-216, 1998
70. 70. COHEN TERVAERT JW, GOLDSCHMEDING R, ELEMA JD, VON DEM BORNE AE, KALLENBERG CGM: Anti-myeloperoxidase antibodies in the Churg-Strauss syndrome. Thorax 46:70-71, 1991
71. 71. GUILLEVIN L, VISSER H, NOËL LH, POURRAT J, VERNIER I, GAYRAUD M, OKSMAN F, LESAVRE P: Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome. J Rheumatol 20: 1345-1349, 1993
72. 72. COHEN TERVAERT JW, LIMBURG PC, ELEMA JD, HUITEMA MG, HORST G, THE TH, KALLENBERG CGM: Detection of autoantibodies against myeloid lysosomal enzymes: A useful adjunct to classification of patients with biopsy-proven necrotizing arthritis. Am J Med 91:59-66, 1991
73. 73. JAYNE DRW, MARSHALL PD, JONES SJ, LOCKWOOD CM: Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int 37:965-970, 1990
74. 74. BOSCH X, MIRAPEIX E, FONT J, BORRELLAS X, RODRIGUEZ R, LOPEZ-SOTO A, INGELMO ML: Prognostic implication of antineutrophil cytoplasmic antibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol 36: 107-113, 1991
75. 75. NÄSSBERGER L, SJÖHOLM AG, JONSSON H, STURFELI G, ÅKESSON A: Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus. Clin Exp Immunol 81:380-383, 1990
76. 76. NÄSSBERGER L, JOHANSSON AC, BJÖRCK S, SJÖHOLM AG: Antibodies to neutrophil granulocyte myeloperoxidase and elastase: Autoimmune responses in glomerulonephritis due to hydralazine treatment. J Intern Med 229:261-265, 1991
77. 77. GUEIRARD P, DELPECH A, GILBERT D, GODIN M, LE LOET X, TRON F: Anti-myeloperoxidase antibodies: Immunological characteristics and clinical associations. J Autoimmun 4:517-527, 1991
78. 78. DOLMAN KM, GANS ROB, VERVAAT TJ, ZEVENBERGEN G, MAINGAY D, NIKKELS RE, DONKER AJM, VON DEM BORNE AE, GOLDSCHMEDING R: Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 342:651-652, 1994
79. 79. GALLICHIO MC, SAVIGE JA: Detection of anti-myeloperoxidase and anti-elastase antibodies in vasculitis and infections. Clin Exp Immunol 84:232-237, 1991
80. 80. ANDRASSY K, RITZ E: Clinical significance of the ANCA test for diagnosis of systemic necrotizing vasculitis, in Renal Involvement in Systemic Vasculitis: Contributions to Nephrology, edited by SESSA A, MERONI M, BATTINI G, Basel, Karger, 1991, pp 22-30
81. 81. KAPLAN-PAVLOVCIC S, VIZJAK A, VENE N, FERLUGA D: Antineutrophil cytoplasmic autoantibodies in atheroembolic disease. Nephrol Dial Tranplant 13:985-987, 1998
82. 82. FALK RJ, HOGAN S, CAREY TS, JENNETTE JC, THE GLOMERULAR DISEASE COLLABORATIVE NETWORK: Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 113:656-663, 1990
83. 83. GOLDSCHMEDING R, COHEN TERVAERT JW, GANS ROB, DOLMAN KM, VAN DEN ENDE ME, KUIZINGA MC, KALLENBERG CGM, VON DEM BORNE AE: Different immunological specificities and disease associations of c-ANCA and p-ANCA. Neth J Med 36:114-116, 1990
84. 84. JENNETTE JC, WILKMAN AS, FALK RJ: Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 135:921-930, 1989
85. 85. SINICO RA, GREGORINI G, RADICE A, CAMPANINI M, POZZI C, QUARENGHI M, NAPODANO P, GIORDANO A, FERRARIO F: Clinical significance of antibodies to myeloperoxidase in vasculitic syndromes, in Renal Involvement in Systemic Vasculitis Contributions to Nephrology, edited by SESSA A, MERONI M, BATTINI G, Basel, Karger, 1991, pp 31-37
86. 86. FAUCI AS, HAYNES BF, KATZ P, WOLFF SM: Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76-85, 1983
87. 87. FIENBERG R, MARK EJ, GODMAN M, MCCLUSKEY RT, NILES JL: Correlation of antineutrophil cytoplasmic antibodies with the extrarenal histopathology of Wegener's (pathergic) granulomatosis and related forms of vasculitis. Hum Pathol 24:160-168, 1993
88. 88. PUSEY CD, GASKIN G: Disease associations with antineutrophil cytoplasmic antibodies, in ANCA-Associated Vasculitides: Immunological and Clinical Aspects, edited by GROSS WL, New York, Plenum Press, 1993. pp 145-155
89. 89. JENNETTE JC, FALK RJ: Antineutrophil cytoplasmic autoantibodies and associated diseases: A review. Am J Kidney Dis 6:517-529, 1990
90. 90. HOFFMAN GS, KERR GS, LEAVITT RY, HALLAHAN CW, LEBOVICS RS, TRAVIS WD, ROTTEM M, FAUCI AS: Wegener's granulomatosis: An analysis of 158 patients. Ann Intern Med 116:488-498, 1992
91. 91. COUSER WG: Rapidly progressive glomerulonephritis: Classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 11:449-464, 1988
92. 92. FRANSSEN CFM, GANS ROB, ARENDS AJ, HAGELUKEN C, TER WEE PM, GERLAG PGG, HOORNTJE SJ: Differences between anti-myeloperoxidase-and anti-proteinase 3 associated renal disease. Kidney Int 47:193-199, 1995
93. 93. GANS ROB, KUIZINGA MC, GOLDSCHMEDING R, ASSMANN K, HUYSMANS FTM, GERLAG PGG, DONKER AJM, HOORNTJE SJ: Clinical features and outcome in patients with glomerulonephritis and antineutrophil cytoplasmic autoantibodies. Nephron 64:182-188, 1993
94. 94. BALDWIN DS, NEUGARTEN J, FEINER HD, GLUCK M, SPINOWITZ B: The existence of a protracted course in crescentic glomerulonephritis. Kidney Int 31:790-794, 1987
95. 95. TAKEDA S, KIDA H, YOKOHAMA H, TOMOSUGI N, KOBAYASHI K: Two distinct types of crescentic glomerulonephritis. Clin Nephrol 37:285-293, 1992
96. 96. SHIN M, YOUNG KR, HO K-J: Wegener's granulomatosis upper respiratory tract and pulmonary radiographic manifestation in 30 cases with pathogenetic consideration. Clin Imaging 22:99-104, 1998
97. 97. BOSCH X, LÓPEZ-SOTO A, MIRAPEIX A, FONT J, INGELMO M, URBANO-MÁRQUEZ A: Antineutrophil cytoplasmic autoantibodies-associated alveolar capillaritis in patients presenting with pulmonary hemorrhage. Arch Pathol Lab Med 118:517-522, 1994
98. 98. HOGAN SL, NACHMAN PH. WILKMAN AS, JENNETTE JC, FALK RJ, THE GLOMERULAR DISEASE COLLABORATIVE NETWORK: Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7:23-32, 1996
99. 99. TER MAATEN JC, FRANSSEN CFM, GANS ROB, HOORNTJE SJ: Respiratory failure in ANCA-associated vasculitis. Chest 110:357-362, 1996
100. 100. STEGEMAN CA, COHEN TERVAERT JW, SLUITER WJ, MANSON WL, DE JONG PE, KALLENBERG CGM: Association of nasal carriage of Staphylococcus aureus and higher relapse rate in Wegener's granulomatosis. Ann Intern Med 20:12-17, 1994
101. 101. COHN TERVAERT JW, HUITEMA MG, HENÉ RJ, SLUHER WJ, THE TH, VAN DER HEM GK, KALLENBERG CGM: Prevention of relapses of Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 336:709-711, 1990
102. 102. KERR GR, FLEISCHER THA, HALLAHAN CW, LEAVITT RY, FAUCI AS, HOFFMAN GS: Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 36:365-371, 1993
103. 103. PETERSON E, HEIGL Z: Anti-neutrophil cytoplasmic antibody (c-ANCA and p-ANCA) titers in relation to disease activity in patients with necrotizing vasculitis: A longitudinal study. Clin Nephrol 37:219-228, 1992
104. 104. JAYNE DRW, GASKIN G, PUSEY CD, LOCKWOOD CM: ANCA and predicting relapse in systemic vasculitis. Q J Med 88:127-133, 1995
105. 105. ARA J, MIRAPEIX E, RODRIGUEZ R, SAURINA A, DARNELL A: Relationship between ANCA and disease activity in small-vessel vasculitis patients with anti-MPO ANCA. Nephrol Dial Transplant 14:1667-1672, 1999
106. 106. KYNDT X, REUMAUX D, BRIDOUX F, TRIBOUI B, BATAILLE P, HACHULLA E, HATRON PY, DUTHILLEUL P, VANHILLE P: Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 106:527-533, 1999
107. 107. FRANSSEN CFM, STEGEMAN CA, OOST-KORT WW, KALLENBERG CGM, LIMBURG PC, TIEBOSCH A, COHEN TERVAERT JW: Determinants of renal outcome in antimyeloperoxidase associated glomerulonephritis. J Am Soc Nephrol 9:1915-1923, 1998
108. 108. WILKOWSKI MJ, VELOSA JA, HOLLEY KE, OFFORD KP, CHU C-P, TORRES VE, MCCARTHY JT JR, DONADIO JV, WAGONDER RD: Risk factors in idiopathic renal vasculitis and glomerulonephritis. Kidney Int 36:1133-1141, 1989
109. 109. ANDRASSY K, ERB A, KODERISCH J, WALDHERR R, RITZ E: Wegener's granulomatosis with renal involvement: Patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. Clin Nephrol 35:139-147, 1991
110. 110. GORDON M, LUQMANI RA, ADU D, GREAVES I, RICHARDS N, MICHAEL J, EMERY P, HOWIE AJ, BACON PA: Relapses in patients with a systemic vasculitis. Q J Med 86:779-789, 1993
111. 111. HEERINGA P, BROUWER E, COHEN TERVAERT JW, WEENING JJ, KALLENBERG CGM: Animal models of anti-neutrophil cytoplasmic autoantibody associated vasculitis. Kidney Int 53:253-263, 1998
112. 112. BROUWER E, HUITEMA MG, KLOK PA, DE WEERD H, COHEN TERVAERT JW, WEENING JJ, KALLENBERG CGM: Anti-myeloperoxidase associated proliferative glomerulonephritis: An animal model. J Exp Med 177:905-914, 1993
113. 113. KALLENBERG CGM: Neutrophils, vasculitis and ANCA. Clin Exp Immunol 112(Suppl 1):2, 1998
114. 114. BROUWER E, HUITEMA MG, MULDER AHL, HEERINGA P, VAN GOOR H, COHEN TERVAERT JW, WEENING JJ, KALLENBERG CGM: Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney Int 45:1120-1131, 1994
115. 115. FALK RJ, TERRELI RS, CHARLES LA, JENNETTE JC: Antineutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87:4115-4119, 1990
116. 116. CHARLES LA, CALDAS MRL, FALK RJ, TERRELI RS, JENNETTE JC: Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol 50:539-546, 1991
117. 117. KEOGAN MT, ESNAULT VLM, GREEN AJ, LOCKWOOD CM, BROWN DL: Activation of normal neutrophils by antineutrophil cytoplasm antibodies. Clin Exp Immunol 90:228-234, 1992
118. 118. MULDER AHL, HEERINGA P, BROUWER E, LIMBURG PC, KALLENBERG CGM: Activation of granulocytes by anti-neutrophil cytoplasm antibodies: A FcγRII-dependent process. Clin Exp Immunol 98:270-276, 1994
119. 119. EWERT BH, JENNETTE JC, FALK RJ: Anti-myeloperoxidase antibodies stimulate neutrophils to damage endothelial cells. Kidney Int 41:375-383, 1992
120. 120. SAVAGE COS, POTTINGER BE, GASKIN G, PUSEY CD, PEARSON JD: Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol 141:335-3-42, 1992
121. 121. JENNETTE JC, FALK RJ: Pathogenic potential of antineutrophil cytoplasmic autoantibodies. Lab Invest 70:135-137, 1994
122. 122. FRANSSEN CFM, HUITEMA MG, MULLER KOBOLD AC, OOST-KORT W, LIMBURG PC, TIEBOSCH A, STEGEMAN CA, KALLENBERG CGM, COHEN TERVAERT JW: In vitro neutrophil activation by antibodies to proteinase 3 and myeloperoxidase from patients with crescentic glomerulonephritis. J Am Soc Nephrol 10:1506-1515, 1999
123. 123. MAYET WJ, MEYER ZUM BUSCHENFELDE KH: Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 94:440-446, 1993
124. 124. MAYET WJ, SCHWARTING A, ORTH T, DUCHMANN R, MEYER ZUM BUSCHENFELDE KH: Antibodies to proteinase 3 mediate expression of vascular cell adhesion molecule-1 (VCAM-I). Clin Exp Immunol 103:259-267, 1996
125. 125. JOHNSSON PA, ALEXANDER HD, MCMILLAN SA, MAXWELL AP: Up-regulation of the endothelial cell adhesion molecule-1 (ICAM-I) by autoantibodies in autoimmune vasculitis. Clin Exp Immunol 108:234-242, 1997
126. 126. DE BANDT M, OLLIVIER V, MEYER O, BABIN-CHEVAYE C, KHECHAI F, DE PROST D, HAKIM J, PASQUIER C: Induction of interleukin 1 and subsequent tissue factor expression by anti-proteinase 3 antibodies in human umbilical vein endothelial cells. Arthritis Rheum 40:2030-2038, 1997
127. 127. BELIZNA C, COHEN TERVAERT JW: Specificity, pathogenicity, and clinical value of antiendothelial cell antibodies. Semin Arthritis Rheum 27:98-109, 1997
128. 128. DEL PAPA N, GUIDALI L, SIRONI M, SHOENFELD Y, MANTOVANI A, TINCANI A, BALESTRIERI G, RADICE A, SINICO A, MERONI PL: Antiendothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion. Arthritis Rheum 39:758-766, 1996
129. 129. MULLER KOBOLD AC, VAN WIJK RT, FRANSSEN CFM, MOLENA G, KALLENBERG CGM, COHEN TERVAERT JW: In vitro upregulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyangiitis. Clin Exp Rheumatol 17:433-440, 1999
130. 130. RASTALDI MP, FERRARIO F, TUNESI S, YANG L, D'AMICO G: Intraglomerular and interstitial leukocyte infiltration, adhesion molecules, and interleukin-1α expression in 15 cases of antineutrophil cytoplasmic autoantibody-associated renal vasculitis. Am J Kidney Dis 27:48-57, 1996
131. 131. SCHMITT W, HEESEN C, CSERNOK E, RAUTMANN E, GROSS WL: Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Arthritis Rheum 35:1088-1096, 1992
132. 132. STEGEMAN CA, COHEN TERVAERT JW, HUITEMA MG, KALLENBERG CGM: Serum markers of T-cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol 91:415-420, 1993
133. 133. WANG G, CSERNOK E, GROSS WL: High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med 102:517-523, 1997
134. 134. FRANSSEN CFM, OOST-KORT WW, STEGEMAN CA, KALLENBERG CGM, COHEN TERVAERT JW: Markers of T-cell and monocyte activation in antiproteinase 3 and antimyeloperoxidase associated crescentic glomerulonephritis, in Antiproteinase 3 and Anti-Myeloperoxidase Associated Systemic Vasculitis: Differences in Clinical Presentation and Pathophysinlogy, Thesis, Franssen CFM, Groningen, 1998, pp 103-115
135. 135. BROUWER E, STEGEMAN CA, HUITEMA MG, LIMBURG PC, KALLENBERG CGM: T-cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis. Clin Exp Immunol 98:448-453, 1994
136. 136. KING WJ, BROOKS CJ, HOLDER R, HUGHES P, ADU D, SAVAGE COS: T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA associated systemic vasculitis and persist during disease remission. Clin Exp Immunol 112:539-546, 1998
137. 137. GRIFFITH ME, COULHART A, PUSEY CD: T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin Exp Immunol 103:253-258, 1996
138. 138. ESNAULI VLM, TESIA A, AUDRAIN M, ROGE C, HAMIDOU M, BARRIER JH, SESBOUE R, MARTIN JP, LESSAVRE P: Alpha I-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 43:1329-1332, 1993
139. 139. SAVIGE JA, CHANG L, COOK L, BURDON J, DASKALAKIS M, DOERY J: α1-Antitrypsin deficiency and anti-proteinase 3 antibodies in anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis. Clin Exp Immunol 100:194-197, 1995
140. 140. GRIFFITH ME, LOVEGROVE JU, GASKIN G, WHITEHOUSE DB, PUSEY CD: C-antineutrophil cytoplasmic antibody positivHy in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-anti-neutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant 11:438-443, 1996
141. 141. SEGELMARK M, ELZOUKI AN, WIESLANDER J, ERIKSSON S: The PiZ gene of alpha I-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. Kidney Int 48:844-850, 1995
142. 142. HOFFMAN GS, SPECKS U: Antineutrophil cytoplasmic antibodies. Arthritis Rheum 41:1521-1537, 1998
143. 143. EDGAR JDM, MCMILLAN SA, BRUCE IN, CONLAN SK: An audit of ANCA in routine clinical practice. Postgrad Med 71:605-612, 1995
144. 144. COLBY TV: ANCA defines the clinical disease manifestations of vasculitis: The "con" side of the issue. Sarcoidosis Vasc Diffuse Lung Dis 13:227-229, 1996
145. 145. GROSS WL, CSERNOK E, HELMCHEN U: Antineutrophil cytoplasmic autoantibodies, autoantigens, and systemic vasculitis. APMIS 103:81-97, 1995